


ABSTRACT

5 The invention relates to novel compounds having formula
(I)



(I)

10 wherein Cy , X , Y , L and R_{1-6} are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.